Scotia Capital’s Enveric Biosciences ENVB Stock Holding History

Scotia Capital’s Portfolio ENVB Stock Details ENVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3	Closed	-$6K	–	801
2022 Q2	$6K	Hold	3	–	–	﹤0.01%	804
2022 Q1	$9K	Sell	3 -4	-57%	-$17.7K	﹤0.01%	871
2021 Q4	$62K	Sell	7 -3	-30%	-$42.2K	﹤0.01%	852
2021 Q3	$195K	Buy	+10	New	+$194K	﹤0.01%	800

Other funds holding ENVB

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Scotia Capital's ENVB Position: Q3 2022 in Review

Scotia Capital sold out of Enveric Biosciences (ENVB) in Q3 2022, closing a stake of 3 shares — an estimated $6K sold.

Scotia Capital first reported a position in ENVB in Q3 2021 and held it in 4 quarters. The position peaked at $195K in Q3 2021. 9 funds tracked by Wall St. Rank hold ENVB as of Q3 2022.

Scotia Capital reported no remaining Enveric Biosciences position as of Q3 2022 after selling out during the quarter.
Scotia Capital sold 3 Enveric Biosciences shares in Q3 2022, an estimated $6K.
Scotia Capital first reported a position in Enveric Biosciences in Q3 2021 and held it in 4 quarters.
Scotia Capital's Enveric Biosciences position peaked at $195K in Q3 2021.
9 funds tracked by Wall St. Rank held Enveric Biosciences as of Q3 2022.

Based on Scotia Capital's 13F filing for Q3 2022, filed 10 Nov 2022.